Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective

Cardiovasc Res. 2002 Mar;53(4):822-30. doi: 10.1016/s0008-6363(01)00503-x.


A milestone in the progression of congestive heart failure (CHF) is myocardial remodeling. Left ventricular (LV) remodeling during the progression of CHF is accompanied by changes in the structure of the myocardial extracellular matrix. Recent clinical and experimental studies have noted that increased release of tumor necrosis factor alpha (TNF-alpha) can contribute to LV myocardial remodeling. Experimental studies have noted that the induction of TNF-alpha can result in LV dilation and proceed to LV pump dysfunction. The biological effects of TNF-alpha are mediated through TNF receptors that are present on all nucleated cells in the heart. TNF receptor activation can induce a number of cellular and molecular events which contribute to LV remodeling in CHF, and include changes in myocyte size and viability and alterations in myocardial structure/composition. In vitro studies have demonstrated that TNF receptor activation can cause the induction of a proteolytic system. This proteolytic system, the matrix metalloproteinases (MMPs), is upregulated in models of LV dysfunction and possesses the capacity to degrade a wide variety of extracellular matrix components. Therefore, one pathway by which TNF-alpha can influence LV myocardial remodeling is through the induction of a specific portfolio of MMP species. Future basic and clinical studies which directly alter TNF receptor activity and measure myocardial MMP species and the relation to LV remodeling will provide new insight into this disease process and future therapeutic modalities.

Publication types

  • Review

MeSH terms

  • Animals
  • Disease Progression
  • Heart Failure / physiopathology*
  • Humans
  • Matrix Metalloproteinases / physiology
  • Signal Transduction
  • Tumor Necrosis Factor-alpha / physiology*
  • Ventricular Remodeling*


  • Tumor Necrosis Factor-alpha
  • Matrix Metalloproteinases